Phone (336) 292-1510
Fax (336) 292-0679

Receive our eNewsletter

  Home  
  Our Team  
  Patient Info  
  Services  

News for Healthier Living

i-Lumen Scientific Announces First U.S. Patient Randomized in i-SIGHT2 Pivotal Study Evaluating Noninvasive Bioelectric Therapy for Intermediate to Advanced Dry AMD

i-Lumen Scientific, Inc., a clinical-stage medical technology company developing bioelectric therapies for retinal disease, today announced the first U.S. patient has been randomized in the i-SIGHT2 pivotal study evaluating the i-Lumen AMD System in patients with intermediate to advanced dry age-related macular degeneration (AMD).

July 21, 2026


July 21 2026

July 20 2026

July 17 2026

July 16 2026

July 15 2026

July 14 2026

July 13 2026

July 12 2026

July 10 2026

July 9 2026

July 8 2026

July 7 2026